Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients

NCT01001832 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Intravenous (IV) abatacept
DRUG: Subcutaneous (SC) abatacept

Sponsor

Bristol-Myers Squibb